Vivlion Signs Worldwide License Agreement for CRISPR/Cas9 Patent Portfolio – Pharmaceutical Technology Magazine
Startup company Vivlion has signed a non-exclusive license agreement with ERS Genomics granting access to CRISPR/Cas9 patent portfolio.
Startup company Vivlion has signed a non-exclusive license agreement with ERS Genomics granting access to CRISPR/Cas9 patent portfolio for the enhancement of Vivlion’s gene editing reagents and screening services.
According to a Dec. 1, 2020 press release, the exclusive license to Geothe University of Frankfurt’s proprietary 3Cs technology for the production of next generation 3Cs CRISPR/Cas gRNA libraries is already held by Vivlion. With the addition of the license from ERS Genomics, Vivlion is now able to offer both R&D reagents and screening services to customers around the world.
“The unique 3Cs technology developed by Vivlion significantly expands the use of CRISPR/Cas libraries for target discovery and drug development,” said Eric Rhodes, CEO of ERS Genomics, in the press release. “It will be exciting to see Vivlion combine its expertise with the power of CRISPR gene editing to facilitate the company’s entry into the global CRISPR/Cas tool market.”
“Our proprietary 3Cs technology enables single and dual-combinatorial CRISPR/Cas libraries in any order of diversity. Due to our unique production process, even complex reagents can be produced without compromising on quality,” added Ivan Ðikic, CEO of Vivlion, in the press release. “Dual combinations of gRNAs may be arranged in a multiplexed, random format or in pre-defined, fixed pairs. Whilst multiplex reagents empower gene interaction and synthetic lethality screening, fixed-pair reagents open the field of high-throughput excision genomics in the coding and non-coding genome.”
Published at Fri, 04 Dec 2020 10:48:39 +0000